Navigation Links
Kendle Announces New Revolving Credit Facility
Date:3/17/2010

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

Forward-Looking Statements

Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995 and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including the statements contained herein regarding anticipated benefits of the new revolving credit facility, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC.  All information in this press release is current as of March 17, 2010. The Company undertakes no duty to update any forward-looking statement to conform the s
'/>"/>

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
2. Kendle to Present at UBS Global Life Sciences Conference
3. Kendle to Present at Robert Baird 2009 Health Care Conference
4. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
5. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
6. Kendle Names Jarrod Pontius Chief Legal Officer
7. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
8. Kendle Announces First Quarter 2009 Results
9. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
10. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
11. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:9/1/2014)... September 01, 2014 The Collaborative ... Diagnostics report provides comprehensive understanding and unprecedented access ... into by the worlds leading life science companies. ... analysis of how and why companies enter collaborative ... prospective partner’s negotiated deals terms provides critical insight ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4
... life sciences ... ... an,agreement to acquire Recombinant Capital, Inc. (Recap), a leading life,sciences subscription ... database that provides more than 1,500,subscribers with access to over 20 ...
... 16 Scimitar Equity, LLC issues a review ... Pipeline of Niche, Cancer Therapies with Billion Dollar ... http://www.scimitarequity.com ., VioQuest Pharmaceuticals is a ... leader in the successful development of,novel drug therapies ...
... from PAREXEL,International Corporation (Nasdaq: PRXL ), a ... than 20,sessions at the Drug Information Association (DIA) ... 22 -- 26, 2008 at the Boston Convention ... global,headquarters office. PAREXEL experts will address key industry ...
Cached Biology Technology:Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm 2Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc. 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 3PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 4PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 6PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 7
(Date:9/2/2014)... professional baseball pitchers with poor core stability are more likely ... because of injury than are pitchers who have good control ... the study, 347 pitchers were assessed for lumbopelvic control during ... they raised a leg to step up were up to ... cumulative, not consecutive during the season than were ...
(Date:9/2/2014)... to prevent Type 2 diabetes, don,t get your hopes up. ... The FASEB Journal , suggests that you don,t ... study compared genetically identical twins-one heavier and one leaner-and found ... those related to Type 2 diabetes, were found in both ... the onset of this type of diabetes is largely influenced ...
(Date:9/2/2014)... the battle between our immune systems and cholera bacteria, ... known as phages. In a new study, researchers from ... National Public Health Laboratory, and elsewhere, report that phages ... in order to survive. Importantly, the study published ... escape from phage predation occurs during human infection. , ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3What you eat and not just the number of calories, is a significant factor in diabetes risk 2War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... (www.ucr.edu) -- Twenty-one undergraduate students in the UC Riverside Bourns ... researching everything from water quality to wildfires to materials that ... lot of opportunities to get involved with research," said Erika ... part in the Summer Bridge program. "This is the reason ...
... Tampa, Fla. (July 26, 2010) Australian ... "reprogrammed" adult mouse fat cells and neural cells to ... of different cells (pluripotency). The cells, called "induced pluripotent ... occurring pluripotent stems cells, such as embryonic stem cells, ...
... which a herpes virus invades cells has remained a mystery ... University of Pennsylvania reveals the unusual structure of a key ... to invade cells. The new map details an essential ... a new target for antiviral drugs. The research was ...
Cached Biology News:Undergrad engineers research everything from water quality to wildfires this summer 2Scientists 'reprogram' mouse fat cells into clinically useful stem cells 2A collaboration solves the herpes virus protein structure providing new drug therapy directions 2A collaboration solves the herpes virus protein structure providing new drug therapy directions 3